CoChat

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed “minimal residual disease”. The phenomenon of disease persistence suggests that despite targeted therapeutic approaches, BCR-ABL-independent mechanisms exist which sustain the survival of leukemic stem cells (LSCs). Although other markers of a primitive CML LSC population have been identified in the preclinical setting, only CD26 appears to offer clinical utility. Here we demonstrate consistent and selective expression of CD93 on a lin − CD34 + CD38 − CD90 + CML LSC population and show in vitro and in vivo data to suggest increased stem cell characteristics, as well as robust engraftment in patient-derived xenograft models in comparison with a CD93 − CML stem/progenitor cell population, which fails to engraft. Through bulk and single-cell analyses of selected stem cell and cell survival-specific genes, we confirmed the quiescent character and demonstrate their persistence in a population of CML patient samples who demonstrate molecular relapse on TKI withdrawal. Taken together, our results identify that CD93 is consistently and selectively expressed on a lin − CD34 + CD38 − CD90 + CML LSC population with stem cell characteristics and may be an important indicator in determining poor TKI responders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-019-0684-5

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CML LSCs are more proliferative than normal HSCs. a A representative sorting strategy of CP-CML samples is depicted. b Fold expansion after 5 days (mean ± standard deviation) are shown (**p < 0.01; ***p < 0.001). c Colony counts are represented (mean ± standard deviation) per 2000 starting cells to allow comparison between groups (*p < 0.05). d Principal component analysis (PCA) of the gene expression profiles from GSE47927 was used to identify global differences between normal and CP-CML. An individual point within the axes represents each microarray and each subpopulation grouping by a different color. Separate PCAs of normal and CP-CML subpopulations. e PCA of normal and CP samples overlapped. f A volcano plot from the same dataset showing the deregulation of genes in a comparison of Lin−CD34+CD38−CD90+ cells from six CP-CML samples compared with three normal samples (GSE47927). Areas of significance are indicated by a dark green (equivalent to q ≤ 0.01) or light green (equivalent to q ≤ 0.05) background. Genes reaching significance are colored red (q ≤ 0.01) or orange (q ≤ 0.05); non-significant genes are gray.
Fig. 1 CML LSCs are more proliferative than normal HSCs. a A representative sorting strategy of CP-CML samples is depicted. b Fold expansion after 5 days (mean ± standard deviation) are shown (**p < 0.01; ***p < 0.001). c Colony counts are represented (mean ± standard deviation) per 2000 starting cells to allow comparison between groups (*p < 0.05). d Principal component analysis (PCA) of the gene expression profiles from GSE47927 was used to identify global differences between normal and CP-CML. An individual point within the axes represents each microarray and each subpopulation grouping by a different color. Separate PCAs of normal and CP-CML subpopulations. e PCA of normal and CP samples overlapped. f A volcano plot from the same dataset showing the deregulation of genes in a comparison of Lin−CD34+CD38−CD90+ cells from six CP-CML samples compared with three normal samples (GSE47927). Areas of significance are indicated by a dark green (equivalent to q ≤ 0.01) or light green (equivalent to q ≤ 0.05) background. Genes reaching significance are colored red (q ≤ 0.01) or orange (q ≤ 0.05); non-significant genes are gray.CC BY · PubMed Central
Fig. 2 CD93 expression can isolate a functional stem cell population in CML. a Analysis of the microarray, GSE47927, demonstrated a significant fold change between CP-CML LSCs and normal HSCs in genes for cell surface proteins. The table represents the most statistically significant cell surface marker genes identified. b RNA from 30 BM and PB CP-CML samples was utilized to validate the gene expression of CD93. MNC and CD34+-selected (n = 30) samples were compared with normal BM (n = 5). c CD93 protein expression was assessed by flow cytometry in lin−CD34+CD38−CD90+ populations between CML (peripheral blood [n = 22] and BM [n = 9]) and normal BM (n = 7). A statistically significant increase in percentage of CD93+ cells in CML was determined using an unpaired Student’s t test (p < 0.0001). MNC; mononuclear cells, PB; peripheral blood, BM; bone marrow.
Fig. 2 CD93 expression can isolate a functional stem cell population in CML. a Analysis of the microarray, GSE47927, demonstrated a significant fold change between CP-CML LSCs and normal HSCs in genes for cell surface proteins. The table represents the most statistically significant cell surface marker genes identified. b RNA from 30 BM and PB CP-CML samples was utilized to validate the gene expression of CD93. MNC and CD34+-selected (n = 30) samples were compared with normal BM (n = 5). c CD93 protein expression was assessed by flow cytometry in lin−CD34+CD38−CD90+ populations between CML (peripheral blood [n = 22] and BM [n = 9]) and normal BM (n = 7). A statistically significant increase in percentage of CD93+ cells in CML was determined using an unpaired Student’s t test (p < 0.0001). MNC; mononuclear cells, PB; peripheral blood, BM; bone marrow.CC BY · PubMed Central
Fig. 3 CD93+, but not CD93−, CP-CML cells have stem cell characteristics in vitro and in vivo. a CP-CML samples (n = 4) were sorted according to Fig. S2 and plated in duplicate into Methocult for 10–12 days prior to colony counts. The graph indicates the mean number of colonies for each CP-CML sample, with mean and standard deviation for each population shown. b 50 primary colonies per sample were replated in Methocult in 96 well plates and incubated at 37°, 5% CO2 for 12 days before positive wells were counted. The graph indicates the percentage of positive wells per population (n = 4 CP-CML samples), with mean and standard deviation shown. c The graph indicates the number of colonies from each experimental arm (n = 3 CP-CML samples), with mean and standard deviation shown. d Representation of in vivo experimental model. CP-CML Lin−CD34+CD93+ or Lin−CD34+CD93− cells were isolated by FACS sorting (1 × 106 cells/mouse), washed and transplanted via tail vein injection into sub-lethally irradiated (2 Gy) 8–12-week-old NSG mice. PB was sampled at 8 weeks to assess for CD45+33+ expression. All mice were euthanized after 16 weeks and marrow contents of femurs were obtained. Cells were labeled with anti-human CD45, CD33, and CD19 antibodies prior to analysis by flow cytometry. This allowed for analysis of lineages within the engrafted samples. e Human myeloid cell engraftment was characterized by the percentage of CD45+CD33+ cells. f Human CD45+ cells were isolated by FACS sorting and analyzed by FISH for the BCR-ABL gene rearrangement. Percentage of BCR-ABL positive cells, as determined from analysis of a minimum of 100 cells, was assessed for each murine experiment.
Fig. 3 CD93+, but not CD93−, CP-CML cells have stem cell characteristics in vitro and in vivo. a CP-CML samples (n = 4) were sorted according to Fig. S2 and plated in duplicate into Methocult for 10–12 days prior to colony counts. The graph indicates the mean number of colonies for each CP-CML sample, with mean and standard deviation for each population shown. b 50 primary colonies per sample were replated in Methocult in 96 well plates and incubated at 37°, 5% CO2 for 12 days before positive wells were counted. The graph indicates the percentage of positive wells per population (n = 4 CP-CML samples), with mean and standard deviation shown. c The graph indicates the number of colonies from each experimental arm (n = 3 CP-CML samples), with mean and standard deviation shown. d Representation of in vivo experimental model. CP-CML Lin−CD34+CD93+ or Lin−CD34+CD93− cells were isolated by FACS sorting (1 × 106 cells/mouse), washed and transplanted via tail vein injection into sub-lethally irradiated (2 Gy) 8–12-week-old NSG mice. PB was sampled at 8 weeks to assess for CD45+33+ expression. All mice were euthanized after 16 weeks and marrow contents of femurs were obtained. Cells were labeled with anti-human CD45, CD33, and CD19 antibodies prior to analysis by flow cytometry. This allowed for analysis of lineages within the engrafted samples. e Human myeloid cell engraftment was characterized by the percentage of CD45+CD33+ cells. f Human CD45+ cells were isolated by FACS sorting and analyzed by FISH for the BCR-ABL gene rearrangement. Percentage of BCR-ABL positive cells, as determined from analysis of a minimum of 100 cells, was assessed for each murine experiment.CC BY · PubMed Central
Fig. 4 Gene expression profiling of bulk CD93-selected CP-CML LSCs confirms their quiescent character. a Schematic diagram of CD93 expression within a stem cell population. b CD93 gene expression as determined in the lin−CD34+CD38−CD90+CD93+ and lin−CD34+CD38−CD90+CD93− population (p = 0.0068). Results are presented as fold change compared with the CD34+ bulk population using the ΔΔCt method. c Key genes involved in lineage restriction were overexpressed in the lin−CD34+CD38−CD90+CD93− population, namely GATA1 and CBX8. d Key genes involved in stem cell maintenance were upregulated in the lin−CD34+CD38−CD90+CD93+ population. e Normalized differential gene expression of the single cells using the ΔΔCt method. The control sample is the mean of the CD93− on each chip. GATA1 was significantly downregulated in the CD93+ population (n = 2 CP-CML samples, q = 0.03). f Principal component analysis (PCA) of the four different populations defined by CD93 surface presence and BCR-ABL1 expression. Each individual dot represents a single cell. It can be observed that the CD93+ BCR-ABL1+ cells (in red) are more heterogeneous than the other populations and that they form a slightly different cluster.
Fig. 4 Gene expression profiling of bulk CD93-selected CP-CML LSCs confirms their quiescent character. a Schematic diagram of CD93 expression within a stem cell population. b CD93 gene expression as determined in the lin−CD34+CD38−CD90+CD93+ and lin−CD34+CD38−CD90+CD93− population (p = 0.0068). Results are presented as fold change compared with the CD34+ bulk population using the ΔΔCt method. c Key genes involved in lineage restriction were overexpressed in the lin−CD34+CD38−CD90+CD93− population, namely GATA1 and CBX8. d Key genes involved in stem cell maintenance were upregulated in the lin−CD34+CD38−CD90+CD93+ population. e Normalized differential gene expression of the single cells using the ΔΔCt method. The control sample is the mean of the CD93− on each chip. GATA1 was significantly downregulated in the CD93+ population (n = 2 CP-CML samples, q = 0.03). f Principal component analysis (PCA) of the four different populations defined by CD93 surface presence and BCR-ABL1 expression. Each individual dot represents a single cell. It can be observed that the CD93+ BCR-ABL1+ cells (in red) are more heterogeneous than the other populations and that they form a slightly different cluster.CC BY · PubMed Central
Fig. 5 TKIs downregulate CD93, but do not eliminate CD93+ LSC even after prolonged in vivo therapy. CP-CML cells (n = 3) were thawed and sorted into an LSC population before culturing in SFM plus physiological growth factors with and without Imatinib (a) or Dasatinib (b). Following culture for 24 h, half of the samples were analyzed by flow cytometry to assess CD93 expression. The rest were thoroughly washed to completely remove TKI and re-cultured in SFM supplemented with physiological growth factors for a further 24 h prior to flow cytometry analysis. c A nilotinib-treated PDX model was used to determine CD93+ cells in the hCD45+CD34+CD38− population by flow cytometry. This demonstrates persistence of CD93 expression despite TKI treatment in two patient samples. d CD93 expression as determined by flow cytometry in eight patients with prolonged TKI treatment. Within patients who relapsed post TKI discontinuation, a small lin−CD34+CD38−CD90+CD93+ population could be identified, compared with patients who did not demonstrate a molecular relapse.
Fig. 5 TKIs downregulate CD93, but do not eliminate CD93+ LSC even after prolonged in vivo therapy. CP-CML cells (n = 3) were thawed and sorted into an LSC population before culturing in SFM plus physiological growth factors with and without Imatinib (a) or Dasatinib (b). Following culture for 24 h, half of the samples were analyzed by flow cytometry to assess CD93 expression. The rest were thoroughly washed to completely remove TKI and re-cultured in SFM supplemented with physiological growth factors for a further 24 h prior to flow cytometry analysis. c A nilotinib-treated PDX model was used to determine CD93+ cells in the hCD45+CD34+CD38− population by flow cytometry. This demonstrates persistence of CD93 expression despite TKI treatment in two patient samples. d CD93 expression as determined by flow cytometry in eight patients with prolonged TKI treatment. Within patients who relapsed post TKI discontinuation, a small lin−CD34+CD38−CD90+CD93+ population could be identified, compared with patients who did not demonstrate a molecular relapse.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 67

Metadata

Authors
Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., Moka, H. A., Dunn, K., Cassels, J. E., Parry, N., Clarke, C. J., Scott, M. T., Clark, R. E., Holyoake, T. L., Wheadon, H., & Copland, M.
Affiliations
  • University of Glasgow (GB)
  • University of Liverpool (GB)
Corresponding author
Copland, Mhairi
Venue
Leukemia
Published
2020-01-02
Volume
34
Issue
6
Pages
1613-1625
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2998081307
Cited by
67
References
40
Citations by year
2026: 3 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 20 · 2020: 4
FWCI
7.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Leukemia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Wellcome Trust (100626/Z/12/Z)
  • Chief Scientist Office (CAF08/09)
  • Bloodwise (11017 and 14033)
  • Kay Kendall Leukaemia Fund (KKL501)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
CD93, chronic myeloid leukemia, leukemia stem cells, minimal residual disease, BCR-ABL tyrosine kinase inhibitors, quiescent stem cells, patient-derived xenografts, molecular relapse, stem cell markers
MeSH terms
Animals, Humans, Membrane Glycoproteins, Receptors, Complement, Biomarkers, Tumor, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Mice, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. https://app.cochat.ai/papers/10.1038/s41375-019-0684-5
The paper
Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., Moka, H. A., Dunn, K., Cassels, J. E., Parry, N., Clarke, C. J., Scott, M. T., Clark, R. E., Holyoake, T. L., Wheadon, H., & Copland, M. (2020). CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia. https://doi.org/10.1038/s41375-019-0684-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.